Effect of a weight loss intervention (WLI) on quality of life (QOL) and symptoms in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.

Journal of Clinical Oncology 2026

View at publisher
Authors: Jennifer A. Ligibel, Dawn L. Hershman, Amylou C. Dueck, Linda Mackie McCall, Brenda Ginos, Pamela Jean Goodwin, Anna Weiss, Olwen Hahn, Patricia Spears, Electra D. Paskett, Judith O. Hopkins, Erica L. Mayer
+8 more Elizabeth S. Frank, Vanessa Bernstein, Vered Stearns, Julia R. White, Thomas A. Wadden, Eric P. Winer, Lisa A. Carey, Ann H. Partridge
DOI: 10.1200/jco.2026.44.16_suppl.12010
Cited by: 1

Abstract

12010 Background: BWEL (Alliance A011401; NCT02750826) is a Phase III trial that randomizes patients (pts) with stage II-III breast cancer and body mass index (BMI) ≥27 kg/m 2 1:1 to a 24-month (mo) lifestyle-based WLI + health education (HE) or HE alone. Here we report prespecified secondary outcomes of the impact of the WLI on patient-reported QOL and symptoms. Methods: The first 540 BWEL pts (randomized between 9/2016 and 7/2017) were included in this substudy that collected PROMIS 29 Profile 2.0 and Global Health scores at enrollment, 6 and 24 mos. Adjusting for baseline scores, mean physical function (predefined substudy primary outcome), global physical and mental health, fatigue and other scores were compared at 6 and 24 mos using analysis of covariance (ANCOVA). P-values

Fields of Study & Subjects

Cancer Risks and Factors Cancer survivorship and care Nutrition and Health in Aging

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
16_suppl
Pages
12010–12010
Publication date
27 May 2026
Language
EN